Where Materials Science Meets Life Sciences Strategy
Advanced materials are reshaping drug delivery, medical devices, and diagnostics. Neucite is the only strategy firm combining materials science depth with life sciences commercial expertise — a combination no competitor offers.
What We Do
Advanced Materials Commercial Strategy
From early-stage positioning to commercial launch, we provide the strategic framework that turns scientific innovation into market leadership.
Therapeutic Innovation Strategy
Identify the highest-value therapeutic areas, map competitive white space, and build a development roadmap that resonates with both regulators and investors.
Fundraising & Investor Positioning
Craft narratives that resonate with Series A through IPO investors. We translate complex biology into commercial opportunity and defensible value propositions.
Regulatory Strategy
Navigate FDA, EMA, and global regulatory pathways with confidence. We help design development programs that minimize risk and accelerate approval timelines.
Partnership & Licensing
Identify, evaluate, and structure pharma partnerships, in-licensing, and out-licensing deals that maximize your asset’s value at every stage.
Market Sizing & Opportunity
Quantify addressable markets, model patient populations, and build defensible commercial projections that hold up under investor and partner scrutiny.
Patent & IP Strategy
Protect your innovations with a comprehensive IP strategy — freedom-to-operate analysis, patent landscaping, and protection of core scientific advances.
How We Help
Real Challenges, Proven Frameworks
Series B Biotech Needed a Clear Commercial Path
A genomics company approaching Series B had strong science but lacked a credible go-to-market story. We built a full commercial strategy — market sizing, competitive positioning, partnership targets — that supported a successful $120M raise.
Platform Biotech Evaluating Multiple Therapeutic Areas
A platform company with broad applicability needed to prioritize. We conducted a 5-indication analysis weighing regulatory risk, competitive intensity, and commercial opportunity, identifying a clear first-mover path.
Pre-Clinical Asset Preparing for Pharma Out-Licensing
A pre-clinical asset team needed to prepare for Big Pharma partnership discussions. We built the full commercial package — target product profile, competitive landscape, deal benchmarking — that resulted in a partnership term sheet within 6 months.
Ready to Accelerate Your Biosciences Strategy?
Whether you’re preparing for fundraising, navigating a partnership, or building your commercial roadmap — let’s talk.